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Abstract: Photodynamic inactivation (PDI) has been used to inactivate microorganisms 
through the use of photosensitizers. The inactivation of mammalian viruses and 
bacteriophages by photosensitization has been applied with success since the first decades 
of the last century. Due to the fact that mammalian viruses are known to pose a threat to 
public health and that bacteriophages are frequently used as models of mammalian viruses, 
it is important to know and understand the mechanisms and photodynamic procedures 
involved in their photoinactivation. The aim of this review is to (i) summarize the main 
approaches developed until now for the photodynamic inactivation of bacteriophages and 
mammalian viruses and, (ii) discuss and compare the present state of the art of mammalian 
viruses PDI with phage photoinactivation, with special focus on the most relevant 
mechanisms, molecular targets and factors affecting the viral inactivation process. 
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Nomenclature 
AlPcS4 
AZT 
BVDV 
DMTU 
EMCV 
HAV 
HBV 
HCV 
HIV 
HPV 
HSV 
LED 
MB 
NM 
NQ 
Pc4 
PDI 
PS 
ROS 
SFV 
SHV 
SOD 
SSB 
Tri-Py+-Me-PF 
VSV 
VZV 
1O2 
3O2 
1PS 
3PS* 
Aluminum phthalocyanine tetrasulfonate 
Azidothymidine 
Bovine viral diarrhea virus 
Dimethylthiourea 
Encephalomyocarditis virus 
Hepatitis A virus 
Hepatitis B virus 
Hepatitis C virus 
Human immunodeficiency virus 
Human papillomatosis virus 
Herpes simplex virus 
Light emitting diode 
Methylene blue 
Not mentioned 
Not quantified 
Silicon phthalocyanine 
Photodynamic inactivation 
Photosensitizer 
Reactive oxygen species 
Semliki Forest virus 
Suid herpes virus 
Superoxide dismutase 
Singlet strand breaks 
5-(pentafluorophenyl)-10,15,20-tris(1-methylpyridinium-4-yl)porphyrin tri-iodide 
Vesicular stomatitis virus 
Varicella zoster virus 
Singlet oxygen 
Molecular oxygen 
Ground state photosensitizer 
Triplet excited state photosensitizer 
1. Introduction 
Humans are exposed to pathogenic viruses through various routes and the development of  
viral-induced diseases is a common occurrence. 
Although the transmission of viral diseases has been reduced by the development of good water 
supplies and hygienic-based procedures for a whole range of human activities [1], pathogenic viruses 
are still the causative agents of many diseases in humans and other species. The most usual human 
diseases caused by viruses include the common cold (coronaviruses), influenza (influenza viruses), 
chickenpox (varicella zoster virus), cold sores (herpes simplex virus), gastroenteritis and diarrhoea 
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(caliciviruses, rotaviruses and adenoviruses) [2,3]. Pathogenic viruses are also implicated in serious 
diseases, such as Ebola (Ebola virus), AIDS (immunodeficiency viruses), avian influenza and sudden 
acute respiratory syndrome (SARS) (SARS-coronavirus), and they are also an established cause of 
cancer (papillomavirus, hepatitis B and C viruses, Epstein–Barr virus, Kaposi’s sarcoma-associated 
herpes virus, human T-lymphotropic virus, and Merkel cell polyomavirus) [4].  
The enhanced implication of viruses in severe infectious diseases and the increasing knowledge 
about the complex mechanisms of viral pathogenesis have greatly contributed to the rapid development 
of antiviral drugs. Consequently, the use of antivirals has largely increased in the last years and 
resistance to antiviral drugs is now well documented for several pathogenic viruses [5–10]. Moreover, 
as viruses are genetically flexible, they may mutate quickly and mutations come as no surprises, 
leading to the development of resistance to conventional antiviral drugs. Consequently, the emergence 
of antiviral drug can become a great problem, such the resistance observed for bacteria relative to 
antibiotics. So, alternative methods unlikely to cause resistance are required. Photodynamic inactivation 
(PDI) of viruses represents a promising and inexpensive potential alternative to meet that need. 
The sensitivity of viruses to photodynamic procedures was reported in the 1930s [11,12] but only 
within the last 30 years, with the development of new active molecules, namely photosensitizers (PS), 
and an increment of light technologies (lasers, LED, portability, etc.), have photodynamic techniques 
for the inactivation of viruses received growing attention [13]. Most of the clinical applications of PDI 
for treatment of infections have so far been directed to viral lesions [14]. Clinical PDI was first applied 
to the treatment of herpes infection in the early 1970s [15], particularly for herpes genitalis. Since then, 
a great variety of viruses has been effectively inactivated by photodynamic treatment using  
in vitro conditions [16] but, considering the clinical use of viral PDI, the procedures are limited to 
the treatment of papillomatosis, caused by human papillomatosis virus (HPV), like laryngeal 
papillomatosis [17] and epidermodysplasia verruciformis [18] and, in a small scale, to the treatment of 
viral complications in AIDS patients [19,20]. However, considerable progress has been made in the 
viral photodynamic disinfection of blood products. The major threat of viral contamination in blood 
and blood products comes from the immunodeficiency viruses (HIV) [21], hepatitis viruses [21–23], 
cytomegalovirus [23], human parvovirus B19 [24] and human T-cell lymphotropic virus type I and 
type II [23]. HIV has been inactivated in vitro following a photodynamic procedure [25–39]. The 
photoinactivation of hepatitis viruses in blood products has also been successfully tested against the 
hepatitis C virus (HCV) [37,40–42], hepatitis B virus (HBV) [43] and hepatitis A virus (HAV) [44]. 
Inactivation of cytomegalovirus [45], human parvovirus B19 [46] and human T-cell lymphotropic 
virus [47] in blood products was also efficiently achieved after photodynamic treatment. 
The availability of a simple and quantitative assay to follow the viral photoinactivation process is 
important. Traditional viral quantification techniques, such as in vitro viral cultures, are time-consuming 
and labor-intensive processes. Molecular quantitative methods such as nucleic acid amplification 
procedures, including real time PCR, are rapid and sensitive but detect only viral nucleic acid and do 
not determine infectivity. When the virucidal properties of different photosensitizing compounds are 
initially evaluated, bacteriophages can be useful as surrogates of mammalian viruses. The reasons for 
their use are: (i) the detection methods are much simpler, faster and cheaper than those of mammalian 
viruses, avoiding the advanced facilities and equipment needed for propagating human pathogens;  
(ii) they are non-pathogenic to humans; (iii) they can be grown to higher titers than most mammalian 
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viruses and, therefore, enhancing the sensitivity of the assay; (iv) the results of bacteriophages assays 
are available within several hours post-inoculation, instead of the days or weeks required by 
mammalian viruses infectivity-based assays; (v) they are at least as resistant as the mammalian viruses 
to environmental factors and to water treatment [48]. 
It has been shown that enveloped viruses are significantly more sensitive to photodynamic 
destruction than non-enveloped viruses [49,50]. As most of the bacteriophages are non-enveloped, they 
are more difficult to suffer photoinactivation than the enveloped viruses. In general, this property 
makes them good indicators to evaluate the efficiency of viral PDI. A PDI protocol that is effective to 
inactivate a non-enveloped phage will most likely be effective against enveloped mammalian viruses. 
Several bacteriophages were used in photoinactivation studies as surrogates for mammalian viruses, 
e.g., MS2 [44], M13 [51,52], PM2 [53], Qβ [54–56], PRD1 [57], λ [58,59], φ6 [60], R17 [60], Serratia 
phage kappa [61], T5 [62], T3 [63], T7 [57,64] and T4-like [65–68], and the results show that they are 
effectively photoinactivated. 
2. Antimicrobial PDI 
PDI is a simple and controllable method for the inactivation of microorganisms based on the 
production of reactive oxygen species (ROS) (free radicals and singlet oxygen). This technology 
requires the combined action of oxygen, light and a photosensitizer (PS), which absorbs and uses the 
energy from light to produce those ROS [69]. Therefore, the photodynamic effects depend on multiple 
variables including: the structural features of the PS, the concentrations of PS and molecular oxygen, 
and the properties of the light used (e.g., wavelength, type, dose and fluence rate) [66,67,69–72]. 
Changes in any of these parameters will affect the rate of microbial photoinactivation [66,67,73,74]. 
The majority of PS used in PDI is derived from tetrapyrrolic macrocycles known as porphyrins. 
These chromophores and their analogs, such as chlorins and bacteriochlorins, are involved in very 
important biological functions, such as respiration (heme group) and photosynthesis (chlorophyll and 
bacteriochlorophyll (Figure 1). Based on these macrocycles, the scientific community was able to 
develop a number of synthetic analogs, such as meso-tetraarylporphyrins, phthalocyanines, texaphyrins, 
porphycenes and saphyrins, which proved to have very promising features for being used as PS (Figure 
2) [16]. Also, non-tetrapyrrolic derivatives, such as the naturally occurring hypericin, or synthetic dyes 
like toluidine blue O, rose bengal, eosin, methylene blue (MB) and fullerenes, were considered in 
many PDI studies (Figure 3) [71]. 
In order to be efficient, photosensitizing agents used for viral PDI must bind specifically to vital 
viral components, such as lipid envelope (when present), the protein coat or to the nucleic acids [55]. 
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Figure 1. Structure of some tetrapyrrolic macrocycles with natural occurrence. 
 
Figure 2. Skeletons of some synthetic pyrrolic macrocycles used as photosensitizers. 
 
Figure 3. Structure of some non-tetrapyrrolic photosensitizers. 
 
 
The efficiency of mammalian viruses and bacteriophages PDI has been described for porphyrin 
derivatives, chlorin derivatives, chlorophyll derivatives, phthalocyanine derivatives, hypericin, 
methylene blue, rose bengal, merocyanine 540, proflavine, and fullerene derivatives (Table 1). 
Viruses 2012, 4 
 
1039 
Table 1. Some PS used for mammalian viruses and bacteriophages PDI. 
Photosensitizer Microorganism PDI Reference 
Mammalian viruses    
Hematoporphyrin derivative HSV-1 7 log [75] 
HSV-1 <0.8 log [36] 
Uroporphyrin Adenovirus 7 log [76] 
Natural metalloporphyrin derivatives HIV-1 <0.8 log [36] 
Chlorophyll derivatives VSV ∼6 log [77] 
7-despropionate-7-hydroxypropylmesopyropheophorbide a BVDV EMCV 
∼5 log 
∼0.2 log [78] 
Benzoporphyrin derivative monoacid ring A HIV-1 >4 log [33] 
Glycoconjugated meso-tetraarylporphyrin derivatives HSV-1 HSV-2 
6 log 
6 log [79] 
Metallo tetrasulfonated meso-tetraarylporphyrin derivatives HIV-1 ≤2 log [36] 
Tetrasulfonated meso-tetraarylporphyrin derivatives HIV-1 ≤2 log [36] HAV ∼4 log [44] 
meso-Tetrakis(1-methylpyridinium-4-yl)porphyrin HAV ∼4 log [44] 
meso-Tetrakis(1-butylpyridinium-4-yl)porphyrin HAV >3.8 log [44] 
meso-Tetrakis(1-octylpyridinium-4-yl)porphyrin HAV >3.9 log [44] 
Cationic β-vinyl substituted meso-tetraphenylporphyrin derivatives HSV-1 <3 log [80] 
Aluminum dibenzodisulfophthalocyanine HIV-1 3.7 log [49] 
Aluminum phthalocyanine tetrasulfonate 
HIV-1 >5 log [49] 
VSV 4.2 log [82] 
Adenovirus 4 log [76] 
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Table 1. Cont. 
Photosensitizer Microorganism PDI Reference 
Mammalian viruses    
Silicon phthalocyanine derivative VSV 4 log [82] 
Cationic phthalocyanines HIV-1 >5 log [49] HSV-1 ≥5 log [83] 
Hypericin 
HIV-1 NQ 
[30] 
VSV 4-5 log 
Influenza virus NQ 
Sendai virus NQ 
Methylene blue 
VSV 4.7 log [81] 
HSV-1 5 log [84] 
SHV-1 2.5 log [84] 
HCV <2 log [41] 
HIV-1 <2 log [41] 
Adenovirus 7 log [76] 
Dengue virus 5–6.4 log [74] 
Enterovirus 71 ∼8 log [85] 
Vaccinia virus 5 log [86] 
Phenothiazine derivatives VSV >4.4 log [60] 
Rose bengal 
Vaccinia virus 5 log [86] 
HIV-1 NQ 
[30] VSV 4–5 log 
Influenza virus NQ 
Sendai virus NQ 
Adenovirus 7 log [76] 
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Table 1. Cont. 
Photosensitizer Microorganism PDI Reference 
Buckminsterfullerene SFV VSV 
7 log 
7 log [50] 
Merocyanine 540 HSV-1 5–6 log [45] 
Bacteriophages 
Glycoconjugated meso-tetraarylporphyrins T7 phage <3 log [64] T7 phage <3.5 log [87] 
Tetrasulfonated meso-tetraarylporphyrin derivatives MS2 phage >3.8 log [44] 
meso-Tetrakis(1-methylpyridinium-4-yl)porphyrin 
λ phage <7 log [58] 
MS2 phage >4.1 log [44] 
T4 phage 7 log [66,67] 
T7 phage <4 log [88] 
5-(pentafluorophenyl)-10,15,20-tris(1-methylpyridinium-4-yl)porphyrin T4 phage 7 log [66–68] 
5-(4-methoxicarbonylphenyl)-10,15,20-tris(1-methylpyridinium-4-yl)porphyrin T4 phage 7 log [66] 
5-(4-carboxyphenyl)-10,15,20-tris(1-methylpyridinium-4-yl)porphyrin T4 phage 3.9 log [66] 
5,10-bis(4-carboxyphenyl)-15,20-bis(1-methylpyridinium-4-yl)porphyrin T4 phage 1.4 log [66] 
5,15-bis(4-carboxyphenyl)-10,20-bis(1-methylpyridinium-4-yl)porphyrin T4 phage 1.2 log [66] 
5,10,15-tris(1-methylpyridinium-4-yl)-20-phenylporphyrin T7 phage 1.7 log [88] 
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Table 1. Cont. 
Photosensitizer Microorganism PDI Reference 
Methylene blue 
Serratia phage 
kappa >4 log [61] 
M13 phage 2.2 log [52,81] 
f2 phage 5 log [56] 
Qβ phage 7–8 log [56] 
Qβ phage 7–8 log [89] 
   
Phenothiazine derivatives R17 phage 
φ6 
4–7 log 
4–6.5 log [60] 
Rose bengal PRD1 phage T7 phage 
∼3.5 log* 
∼4.5 log* [57] 
Riboflavin λ phage <4 log [59] 
Proflavine 
Serratia phage 
kappa 4 log [61] 
T3 phage 7–11 log [63] 
Polyhydroxylated fullerene 
MS2 phage ∼4 log [90] 
PRD1 phage 
T7 phage 
MS2 phage 
∼2.5 log* 
∼3.5 log* 
∼5 log* 
[57] 
*log(N/N0) 
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Besides this, viral PDI has also been described for phthalocyanine derivatives [81], methylene blue 
[53,62,91,92], toluidine blue O [53,62,93], neutral red [93], proflavine [93], azure B [53] and 
merocyanine 540 [45,47,94]. 
3. Mechanisms of Photodynamic Inactivation 
The mechanisms of PDI are based on the ability of the PS to absorb energy from light and transfer 
that energy to molecular oxygen. In the dark, the electronic configuration of a PS exists in the so-called 
ground state. The absorption, by the PS, of a photon at an appropriate wavelength initially leads to the 
production of an unstable, electronically-excited state of the PS molecule (the lifetime of this state 
ranges from 10−9 to 10−6 s) [95]. The excited PS molecule can then decay to the ground state by 
emission of light (radiative pathway - fluorescence) or by intersystem crossing, affording the excited 
triplet state which has a longer lifetime (10−3 to 10 s) [95]. At this point, the PS can reach the ground 
state either by spin inversion followed by phosphorescence emission, or by a non-radiative process. 
Due to the longer lifetime of the PS triplet state, this excited state can also react in one of two ways 
(Figure 2): by initiating photochemical reactions that can directly generate reactive oxygen species 
(ROS) (type I pathway), or indirectly by energy transfer to molecular oxygen (type II pathway), 
leading to the formation of singlet oxygen (Figure 4). These events afford toxic species which are 
responsible for the irreparable oxidative damages induced to important biological targets [1,69,95,96]. 
Figure 4. Schematic representation of the photosensitization process (adapted from [97]). 
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3.1. Type I and Type II Mechanisms 
Type I mechanism involves hydrogen-atom abstraction or electron-transfer between the excited PS 
and a substrate, yielding free radicals [Equations (1) and (2)]. These radicals can react with oxygen to 
form active oxygen species, such as the superoxide radical anion [Equation (3)]. Superoxide is not 
particularly reactive in biological systems but, when protonated, can lead to the production of 
hydrogen peroxide and oxygen [Equations (4) and (5)] or highly reactive hydroxyl radicals 
[Equations (6)–(8)] [98]. Type II photooxidation is considerably less complex mechanistically than 
type I and in general there are far fewer products [99]. In this pathway, the excited triplet state PS 
(3PS*) can transfer the excess energy to molecular oxygen (3O2) and relax to its ground state (1PS) 
creating an excited singlet molecular oxygen (1O2) [Equation (9)] [69]. 1O2 is highly electrophilic and 
can interact with numerous enzymes, leading to the inhibition of protein synthesis and molecular 
alteration of DNA strands, which alters the transcription of the genetic material during its replication 
(mutagenic effect) and, in this way, leading to microbial death [Equation (10)] [98,100]. Like nucleic 
acids and proteins, unsaturated lipids are also prominent targets of 1O2 and free radical attack. Lipid 
peroxidation-ensuing reactions can alter surrounding proteins, nucleic acids and other molecules, in 
addition to the lipids themselves [98]. Therefore, it is likely that damage of different kinds caused to 
the viral envelope is important in the process of microbial inactivation [13].  
SubstrateH2 + PS  PSH + SubstrateH (1) 
PS* + Substrate  PS− + Substrate+ or PS* + Substrate  PS+ + Substrate− (2) 
PS− + 3O2  PS + O2− (3) 
O2− + H+ ⇋ HOO (4) 
2 HOO  H2O2 + O2 (5) 
H2O2 + Fe2+  HO + OH− + Fe3+ (6) 
BiomoleculeH + HO  Biomolecule + H2O (7) 
Biomolecule + 3O2  Biomolecule-OO  products (8) 
PS* + 3O2  PS + 1O2 (9) 
Biomolecules + 1O2  oxidative products (10) 
Both type I and type II mechanisms can occur simultaneously or exclusively, and the ratio between 
these processes depends on the PS used and on the concentrations of substrate and oxygen [95]. The 
competition between organic substrates and molecular oxygen for the 3PS* determines whether the 
reaction pathway is type I or type II and the predominant mechanism can be changed during the course 
of the PDI process [101].  
3.2. Evaluation of the Specific Involvement of Type I and Type II Mechanisms 
An important goal in the investigation of viral PDI is to identify the type of mechanism involved 
(type I or type II) in the presence of a selected PS [102]. The simple detection of a reactive species 
does not necessarily explain the mechanism by which a specific PS induces the toxic effect. It is 
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generally easier to draw a negative conclusion, i.e., if singlet oxygen is absent, it cannot be the reactive 
species responsible for the photodynamic effect [103]. The simplest approach for determining whether 
singlet oxygen (type II mechanism) or free radicals (type I mechanism) is involved in the 
photodynamic process is to study the inhibitory effects of various scavengers, i.e., compounds that can 
intercept these ROS at high rates and in a putatively selective manner [99,101,104]. 
3.2.1. Type I Mechanism Scavengers 
A first line of defence against ROS is, of course, the protection against their formation. However, 
the interception of the damaging species once formed, to prevent it from further deleterious reactions, 
is also a deactivation strategy of defence. In general, free radical scavengers neutralize the radical 
species by donating one of their own electrons. The quenching agents themselves are not particularly 
toxic before and after the electron donation [105]. 
Three different types of quenching are possible, which include the transfer of the radical character 
with the formation of a reactive scavenger-derived radical; trapping of free radicals with the formation 
of a stable or inert free radical trap; and molecules which mimic quenching enzyme activities. In 
general, scavenger molecules either prevent free radicals from being formed or remove them before 
they can damage vital molecular components [105]. 
Several free radical scavengers have been used to evaluate the specific involvement of type I 
mechanism during mammalian viruses and bacteriophages PDI with different PS (Table 2). 
Table 2. Free radical scavengers used in mammalian viruses and bacteriophages PDI. 
PS Scavenger Microorganism 
Scavenger 
protection 
Reference 
Mammalian viruses     
Aluminum phthalocyanine 
tetrasulfonate 
Reduced glutathione 
Mannitol 
Glycerol 
SOD 
VSV 
 
Little/no effect 
Little/no effect 
Little/no effect 
Little/no effect 
[106] 
Polyhydroxylated fullerene 
Glutathione (2.0 mM) 
SFV 
VSV 
no effect 
no effect 
[50] 
Hydroquinone (2.0 mM) 
SFV 
VSV 
no effect 
no effect 
[50] 
Merocyanine 540 
Glutathione (10 and 30 mmol L−1) 
Cysteamine (10 and 30 mmol L−1) 
SOD (1.5 to 29 U mL−1) 
HSV-1 
30-50% 
60-70% 
no effect 
[45] 
Methylene blue 
Mannitol (100 mM) 
Glycerol (10 mM) 
SOD (300 U mL−1) 
Catalase (30 U mL−1) 
HSV-1 
24% 
24% 
24% 
24% 
[84] 
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Table 2. Cont. 
PS Scavenger Microorganism 
Scavenger 
protection 
Reference 
Bacteriophages     
5,10,15-(4-β-D-glucosylphenyl)-
20-phenylporphyrin 
DMTU (0.1–5.0 mM) T7 phage 44% [64] 
5,10.15,20-Tetrakis(4-β-D-
glucosylphenyl) porphyrin 
DMTU (0.1–5.0 mM) T7 phage 79% [64] 
5,10,15-(4-β-D-
galactosylphenyl)-20-
(pentafluorophenyl)-porphyrin 
DMTU (0.1–5.0 mM) T7 phage 89% [87] 
5-(pentafluorophenyl)-10,15,20-
tris(1-methylpyridinium-4- 
yl)porphyrin 
D-mannitol (100 mM) 
T4 phage  
Qβ 
20%  
no effect 
[107] 
L-cysteine (100 mM) T4 phage 9% [107] 
5,10,15,20-tetrakis(1-
methylpyridinium-4-yl)porphyrin 
D-mannitol (100 mM) T4 phage no effect [107] 
Proflavine L-cysteine (0.025 M) T3 phage 75–80% [63] 
Polyhydroxylated fullerene SOD MS2 phage no effect [90] 
3.2.1.1. Free Radicals in PDI of Mammalian Viruses  
Free radical species had, in general, little or no effect on the photoinactivation of the studied 
mammalian viruses (Table 2). In fact, it can be observed that the rate of inactivation of 
HSV [45,84,106], influenza virus [108], Semliki Forest virus (SFV) and VSV [50] in the presence of 
different PS and scavengers like glutathione, D-mannitol, glycerol, superoxide dismutase (SOD), 
catalase and hydroquinone was not significantly affected. Although this data suggest that free radicals 
are not major players in the viral inactivation process, the participation of type I reaction pathways 
cannot be ruled out, as was shown by the considerable level of protection afforded by glutathione and 
cysteamine when merocyanine 540 was used as PS for inactivation of HSV-1 [45]. 
3.2.1.2. Free Radicals in PDI of Bacteriophages  
The photoinactivation rate of some bacteriophages can be reduced in the presence of free radical 
scavengers, suggesting a contribution of radical species in the inactivation process (Table 2). In 
particular, it was reported that the inhibition of T7 phage photoinactivation in the presence of 
glycoconjugated meso-tetraarylporphyrins varied according to the structure of the PS and the 
concentration of dimethylthiourea (DMTU) [64,87]. In fact, T7 phage PDI by meso-tetrakis(4-β-D-
glucosylphenyl)porphyrin [64] and 5,10,15-(4-β-D-galactosylphenyl)-20-(pentafluorophenyl)porphyrin 
[87] seemed to be mainly mediated by free radical species, as revealed by the protection effect of free 
radical scavenger DMTU, contrary to T7 phage photosensitization by 5,10,15-(4-β-D-glucosylphenyl)-
20-phenylporphyrin, which revealed a significantly smaller contribution from type I mechanism. The 
highest inhibition was reached at about 1.0 mM of DMTU; further increase in scavenger concentration 
did not decrease the slope of photoinduced inactivation of phages. However, in spite of inhibiting the 
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efficacy of the PS, DMTU did not completely inhibit T7 phage PDI [64,87]. Similar results were 
reported for T3 phage in the presence of L-cysteine as the scavenger and proflavine as the PS. 
However, the photoinactivation rate of MS2 by a polydroxylated fullerene was not affected by the 
presence of SOD, suggesting a negligible contribution of radical species, such as the superoxide 
radical anion [90]. T4-like phage PDI was also little or not affected by the presence of free radical 
scavengers L-cysteine and D-mannitol in the presence of porphyrin derivatives, leading to the 
conclusion that free radical species are not major participants in phage PDI [107]. 
3.2.2. Type II Mechanism Quenchers 
In general, the action of chemical singlet oxygen quenchers involves the reaction of singlet oxygen 
with the quenching agent, producing an oxidized product. Another possibility is the deactivation of 
singlet oxygen to ground state (3O2) by physical quenching, achieved by either energy or charge 
transfer, without consumption of oxygen or product formation [101,109]. Residues of histidine, 
tryptophan and tyrosine in proteins are considered to be major natural quenchers of singlet oxygen [110]. 
Several singlet oxygen quenchers have been used to evaluate the specific involvement of type II 
mechanism during viral PDI with different PS (Table 3). 
Table 3. Singlet oxygen quenchers used on mammalian viruses and bacteriophage PDI. 
PS Quencher Microorganism 
Quencher 
protection 
Reference 
Mammalian viruses     
Aluminum phthalocyanine 
tetrasulfonate 
Sodium azide 
Tryptophan 
VSV 
VSV 
significant effect 
Significant 
effect 
[106] 
Rose bengal 
β-carotene 
Sodium azide 
Influenza virus 
Significant 
effect 
[108] 
Hypericin Sodium azide HIV 
Significant 
effect 
[111] 
Methylene blue Imidazole (5.0 and 10 mM) HSV-1 55–75% [84] 
Bacteriophages     
5,10,15-(4-β-D-galactosylphenyl)-20-
(pentafluorophenyl)porphyrin 
Sodium azide (0.1–5.0 mM) T7 phage 38% [87] 
5-(pentafluorophenyl)-10,15,20-tris(1-
methylpyridinium-4-yl)porphyrin 
Sodium azide (100 mM) 
T4 phage 
Qβ 
80% 
39% [107] 
L-histidine (50 mM) T4 phage 74% 
meso-tetrakis(1-methylpyridinium-4-
yl)porphyrin 
Sodium azide (100 mM) T4 phage 90% 
[107] 
L-histidine (100 mM) T4 phage 78% 
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Table 3. Cont. 
PS Quencher Microorganism 
Quencher 
protection 
Reference 
Bacteriophages     
5,10,15,20-Tetrakis(4-β-D-
glucosylphenyl)porphyrin 
1,3-diphenylisobenzofuran 
(0.1-5.0 mM) 
T7 phage 42% [64] 
5,10,15-(4-β-D-glucosylphenyl)-20-
phenylporphyrin 
1,3-diphenylisobenzofuran 
(0.1-5.0 mM) 
T7 phage 74% [64] 
Polyhydroxylated fullerene 
β-carotene 
T7 phage 
PRD1 phage 
69% 
56% 
[57] 
β-carotene (26 µM) MS2 phage 50–60% [90] 
Rose bengal Sodium azide (3.5–35 mM) M13 phage 31% [52] 
3.2.2.1. Singlet Oxygen in PDI of Mammalian Viruses  
Singlet oxygen seems to be the most important mediator of virucidal activity (Table 3) on 
mammalian viruses. The rate of viral photoinactivation is significantly inhibited by oxygen removal or 
by addition of singlet oxygen quenchers, such as β-carotene, imidazole, L-histidine or sodium azide 
[45,84,106–108]. Hypericin may induce photochemical alterations on HIV major capsid protein p24, 
which are inhibited by sodium azide, suggesting that the damage results from singlet oxygen [111]. 
When merocyanine 540 [45], phthalocyanine derivatives [106] or rose bengal [108] were used as PS, 
the results suggest that 1O2 is the main cytotoxic species involved in VSV photoinactivation, while 
type I reactants such as hydroxyl radicals are less important. 
3.2.2.2. Singlet Oxygen in PDI of Bacteriophages  
Considering the PDI of bacteriophages in the presence of singlet oxygen quenchers, the results 
(Table 3) suggest that, in most of the studied cases, singlet oxygen is an important mediator of the 
toxic effect induced by PDI. However, the participation of free radicals cannot be ruled out. For 
instance, the inactivation of M13 bacteriophage by MB was inhibited from 1.72 log to 0.54 log by 
sodium azide in a quencher dose-dependent mode, up to a concentration of 3.5 mM. However, 
photoinactivation occurred even in the presence of sodium azide, suggesting that both type I and type 
II mechanisms may be involved in the M13 photoinactivation process. In the presence of quencher 
concentrations ranging from 3.5 to 35 mM, a sodium azide protective effect was not observed, as 
evidenced by increasing rates of M13 phage photoinactivation, reaching a plateau thereafter [52]. Also, 
the effect of singlet oxygen quenchers and of hydrogen peroxide indicated singlet oxygen as the main 
factor responsible for the loss of biological activity of bacteriophage M13 by rose bengal [51]. 
The efficiency of 5,10,15-(4-β-D-galactosylphenyl)-20-(pentafluorophenyl)porphyrin to photoinactivate 
T7 phage decreased in 38% in the presence of sodium azide [87]. This result, and the ones obtained in 
the presence of DMTU (Table 2), proved that for this PS, both mechanisms play a role in T7 
phage photoinactivation, with type I being the predominant one. Similar results were obtained by  
Gábor et al. [64] in the presence of glycoconjugated meso-tetraarylporphyrin derivatives as PS and 
using 1,3-diphenylisobenzofuran as the singlet oxygen quencher. When T7 phage was phototreated 
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with 5,10,15,20-tetrakis(4-β-D-glucosylphenyl)porphyrin, the rate of inactivation decreased 42% in the 
presence of 1,3-diphenylisobenzofuran. When 5,10,15-(4-β-D-glucosylphenyl)-20-phenylporphyrin 
was used, the rate of protection substantially increased (74%). It can then be concluded that the type of 
PDI mechanism depends on the PS structure, with the symmetric derivative exerting its toxic effect 
mainly via the generation of free radicals, whether the asymmetric derivative proceeds mainly by 
singlet production [64]. However, in the study of Egyeki et al. [87] using the same asymmetric 
5,10,15-(4-β-D-galactosylphenyl)-20-(pentafluorophenyl)porphyrin as PS, and the same phage, the 
toxic effect occurred mainly via free radical generation. Besides this, the contribution of type I and 
type II processes was PS concentration-dependent and the sum of the photoinactivation rate measured 
in the presence of scavengers was smaller than the one measured without the scavengers. This result 
may imply a synergism between singlet oxygen and hydroxyl radical-mediated damages or it can also 
be supposed that the efficiency of neither scavenger is 100% [64,87]. 
A recent study showed that irradiation of polyhydroxylated fullerene suspensions (40 µM) in the 
presence of β-carotene reduced the photoinactivation rate of PRD1 and T7 phages, demonstrating 
singlet oxygen involvement [57]. Also, when the T4-like phage was irradiated in the presence of 
porphyrin derivatives and singlet oxygen quenchers sodium azide and L-histidine, the rate of phage 
inactivation was considerably reduced, suggesting that singlet oxygen may be an important mediator 
of the virucidal activity of these PS [107]. However, from the data obtained, other inactivation 
mechanisms cannot be excluded [57,107]. 
Although some data about the importance of the type I and II mechanisms in PDI of bacteriophages 
are discrepant, in general, it seems that the type II pathway is more important than the type I 
mechanism in phage PDI. On the other hand, there are only a few studies focusing on the simultaneous 
effect of singlet oxygen and free radicals scavengers under the same protocol of viral PDI 
[64,84,87,90,106,107]. 
4. Molecular Targets of Antiviral PDI 
The short-lived ROS generated by photodynamic mechanisms are responsible for the damage 
induced to critical molecular targets [112]. Different viral targets, such as the envelope lipids and 
proteins, capsid and core proteins and the nucleic acid can be attacked by singlet oxygen and/or other 
ROS (hydrogen peroxide, superoxide and hydroxyl radicals) to achieve the loss of infectivity [84]. For 
a better understanding of the photoinactivation process, the knowledge of how the molecular targets 
are affected by PDI assumes a great importance [113]. For this reason, a detailed photophysical and 
photochemical study of the interactions between the toxic species generated by the PS and key 
biomolecules such as lipids, proteins and nucleic acids is essential for the knowledge and prediction of 
photosensitization process efficiency [114]. However, the studies performed show that the primary 
target of PDI depends on the chemical structure of the PS, the targeted virus and the mechanism of 
photoinactivation [64].  
4.1. Nucleic Acids 
Depending upon the viruses, the nucleic acid can be either DNA or RNA (single or double 
stranded). The size of the nucleic acid also varies depending on the viruses. Several studies have 
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shown that both DNA and RNA mammalian viruses and phages are efficiently inactivated by PDI. 
There is now considerable information that PS like MB can bind to and penetrate viral membranes, 
whereupon they intercalate with nucleic acids. Upon activation by light, the generated ROS can cause 
the destruction of the nucleic acids, particularly at guanine residues, preventing viral replication [115]. 
However, there is a difference in target selectivity depending on the mechanism involved: sugar 
moieties are usually attacked by radicals (generated via type I process) and guanine residues are the 
targets of singlet oxygen (generated via type II process) [97]. 
4.1.1. DNA Damage 
From the four DNA bases, guanine is the most susceptible component to suffer a type I 
photosensitization reaction, due to the fact that it exhibits the lowest oxidation potential among DNA 
bases and it is the only base that can be oxidized by singlet oxygen (type II process) [116]. 
The treatment of viruses with MB and other heterocyclic dyes resulted in the damage of viral DNA 
[53,65,75,76] either by base modification or base loss, single strand breaks (SSB), or cross-links of 
DNA with proteins [34,75,81,88,117]. It is known that cationic porphyrins can bind to nucleic acids 
via intercalation into base pairs or self-stacking, inducing lesions upon photoinactivation due to the 
easy oxidation of guanine residues [118–120]. 
The binding of cationic porphyrins to DNA is presumably due to the electrostatic interaction 
between the positively-charged substituents in the porphyrin macrocycle and the negatively charged 
phosphate oxygen atoms of DNA [120]. However, porphyrin binding to DNA is not a prerequisite for 
an efficient photosensitization, since free porphyrins are more effective in virus inactivation than the 
DNA-bound species [88]. This observation, which is in conflict with the generally accepted idea that 
the porphyrin molecule must be in close vicinity with the site of photosensitized damage, may be 
explained by the lower quantum yield of singlet oxygen by the bound porphyrin when compared with 
the free one [88]. 
4.1.1.1. Damages in the DNA of Mammalian Viruses 
Viral DNA is thought to be a critical target structure for PDI by MB and light [93]. DNA isolated 
from adenovirus treated with 1.3 µM MB exhibited a smear in Southern blot analysis, indicative of 
random DNA fragmentation [76]. MB plus light treatment of HSV-1 gives rise to DNA damage and 
blocks DNA replication [121].  
4.1.1.2. Damage in the DNA of Bacteriophages 
An internal component of T4 phage has been suggested as an important target because MB needs to 
cross the outer barrier made by its protein capsids in order to produce a significant effect [65]. In fact, 
some of the irradiated phages could still inject functional genetic material but have lost their ability to 
form plaques, suggesting that their DNA was damaged. Protein synthesis was also severely impaired 
[65]. Treatment of M13 phage with MB and aluminum phthalocyanine tetrasulfonate (AlPcS4) caused 
strand breaks and piperidine-labile bonds in DNA, which is correlated with the loss of infectivity. This 
is in agreement with the proposal that lesions of the viral genome might be responsible for the lethality 
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induced by sensitization [81]. DNA strand cleavage was found to be MB concentration and light dose 
dependent. Viral inactivation and DNA damage were found to be oxygen-dependent processes. 
However, DNA damage was not correlated with the loss of PM2 phage infectivity, as observed in 
transfection studies which measured the infectivity of the extracted viral DNA, indicating that DNA 
from MB-treated phage was just as capable of generating progeny virus as the untreated controls [53]. 
The observed DNA damage is not correlated with loss of phage infectivity and may not be the prime 
target of viral PDI, because 100% of closed circular DNA was recovered from the MB phototreated 
PM2 phage [53]. Concerning the effects of PDI on isolated viral DNA, treatment of M13mp2 DNA 
with increasing concentrations of MB, in the presence of light, yielded increasing amounts of  
8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodguo), a prevalent adduct produced by singlet oxygen and 
perhaps by oxygen free radicals. At 100 µM MB, 1 residue of 8-oxodguo was produced for every 
40 residues of deoxyguanosine in DNA. Thus, treatment of M13mp2 DNA with MB plus light resulted 
in putative alterations at deoxyguanosine residues that impede the progression of DNA synthesis  
in vitro [116]. 
4.1.2. RNA Damage 
RNA has been suggested to be a key factor in viral PDI with many PS, but direct evidence of a 
correlation between RNA damage and infectivity loss has not been reported yet, as is the case of VSV 
when treated with phthalocyanine derivatives [81]. In RNA, as for DNA [71], guanine is suggested as 
the major target for oxidation by photosensitizing agents and light.  
4.1.2.1. Damage in the RNA of Mammalian Viruses 
VSV genome was damaged by 30 µg mL−1 of a chlorophyll derivative and red light illumination 
which caused a decrease of as much as 85% in RNA polymerase activity, which can be due to damage 
in the viral RNA polymerase complex, and 98% inhibition of viral RNA synthesis in 6 hours [77]. 
According to Moor et al. [82], the RNA and/or the RNA polymerase complex of VSV might be a 
major target for its photoinactivation by AlPcS4 and MB. MB and phthalocyanine derivatives 
inactivated VSV and inhibited fusion of the virus envelope with Vero cells. The degree of inhibition 
was small compared to the extent of virus inactivation, suggesting that non-membrane targets, like the 
viral RNA, might be involved in VSV photoinactivation. However, there is no report of a correlation 
between RNA damage and loss of infectivity [81]. Photoinactivation of HIV-1 by MB and light lead to 
destruction of its RNA [34]. 
4.1.2.2. Damage in the RNA of Bacteriophages 
Following MB plus light exposure, the Qβ RNA genome exhibited sufficient lethal lesions to 
account for phage inactivation [122]. However, the protein component of the phage also exerted some 
effect in viral PDI [122]. In a comparison of RNA photoinactivation using MB and rose bengal as the 
PS, Schneider et al. [54] suggested a causal relationship between 8-oxodguo formation in RNA and 
R17 and Qβ bacteriophage inactivation. However, no direct relationship between photodynamically 
induced RNA damage and viral inactivation was described [54]. 8-oxodguo formation or oxidative 
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damage of Qβ RNA alone does not directly account for the lethal event of the virus. Directly treating 
extracted phage RNA with MB and light caused a loss of activity in the infectious RNA assay but there 
was a much greater loss of activity if the phage RNA was treated with MB and light in the phage per se. 
The results demonstrated that Qβ RNA infectious activity is significantly more affected by 
photoinactivation in its protein-associated virion state as compared with its purified isolated polymer 
state [92,122]. Inactivation of purified RNA by MB and light, in the absence of proteins, most likely 
occurs due to oxidative damage to the RNA at the site at which MB is bound and might involve 
oxidized bases such as 8-oxoguanine or strand breaks [122]. 
In spite of the reduced number of reports focusing on the damage induced by PDI in the nucleic 
acids of mammalian viruses and bacteriophages, it can be concluded that both DNA and RNA are 
potential targets of viral PDI. However, there are no studies specifically focusing on the damages 
induced to DNA and RNA of both mammalian viruses and bacteriophages under the same PDI protocol. 
4.2. Outer Structures 
Enveloped viruses are inactivated more rapidly than non-enveloped viruses because the destruction 
of the envelope structure is generally accompanied by loss of virus infectivity [13,40,94,123,124]. The 
damages caused by photodynamic reactions on unsaturated lipids present in their envelopes and/or on 
major envelope proteins, which act as PS binding-sites, modify their structure and avoid cell infection 
and virus replication [50,84]. However, some studies showed that non-enveloped viruses can also be 
efficiently inactivated by the toxic action of PS [55,56,58,62,64–67,73,81,87,88,94,122]. 
The higher susceptibility to PDI of enveloped viruses, relatively to non-enveloped viruses, indicates 
that the viral envelope may be a more important target than nucleic acids for photosensitization. It also 
indicates that the unsaturated lipids present in the envelope, as well as the major envelope proteins, are 
important PDI targets. However, as far as it is known, no studies focus on the degradation of viral 
envelope lipids after PDI or even on other viral internal lipids. There are, however, many studies about 
the effects of PDI on viral envelope proteins as well as on other core proteins. 
The statement that enveloped viruses are more easily inactivated than non-enveloped ones is only 
based in indirect studies which compare the inactivation results of enveloped and non-enveloped 
viruses. The enveloped viruses used in PDI protocols [30,36,45,77,81–83] were only assayed for their 
protein alterations and no additional experimental work was done concerning their lipids. However, the 
results of PDI obtained by Lytle et al. [94] with the enveloped φ6 phage, although indirectly, are in 
good accordance with what is reported in the literature about the major contribution from lipids for the 
viral photoinactivation process.  
Relative to proteins degradation by PDI, the results of different studies showed that the main 
damage is the formation of protein cross-links, followed by other types of damage, which include loss 
of proteins, alterations in protein molecular conformation, mass and charge, and alterations in protein 
band intensity (Table 4). 
When proteins are irradiated with UV or visible light in the presence of a PS, photooxidation of 
sensitive amino acid residues such as cysteine, L-histidine, tyrosine, methionine and tryptophan, and 
covalent cross-linking of peptide chains can be observed, leading to the formation of molecular 
aggregates [125,126], disrupting their normal folding conformation, thus forcing them into other 
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conformations that affect their normal functioning [127]. In fact, the formation of cross-
linked/aggregated material appears to be a major consequence of photosensitized-mediated protein 
oxidation [128], and it has been demonstrated that the formation of protein cross-links is not a primary 
photodynamic event, but a secondary reaction between the photooxidation products of sensitive amino 
acid residues and other groups in the protein [126]. 
The PS per se can induce alterations in the folding of some enzymes, leading to the exposure of 
some amino acid residues normally shielded in the protein, and to the shielding of others usually 
exposed in the molecule. These protein modifications lead to changes in properties such as solubility, 
proteolytic susceptibility, absorbance, and fluorescence emission of several of their amino acids. These 
alterations are mainly mediated by hydrogen peroxide and hydroxyl radical generation, although 
singlet oxygen mediated reactions could also occur [129]. The amino acids located in the surface of the 
protein are photooxidized at a much faster rate than the residues buried in the interior of the molecule. 
If a protein is completely unfolded, susceptible amino acids may also be attacked and photodegraded 
[103,130]. 
Table 4. Degradation of viral outer structures after mammalian viruses and bacteriophages PDI. 
Virus Type of damage PS Reference 
Enveloped-
mammalian viruses 
   
HSV-1 
Viral envelope (reduced ability to adhere to and 
penetrate host cells) 
Merocyanine 540 [45] 
Viral envelope (prevention of viral adsorption 
and host penetration) 
Phthalocyanine derivatives [131] 
Glycoprotein D; loss of proteins; dimerization; 
protein cross-links; alterations in protein 
molecular mass and charge 
Phthalocyanine derivatives [83] 
HSV-2 
Viral envelope (prevention of viral adsorption 
and host penetration) 
Phthalocyanine derivatives [131] 
HSV Protein cross-links Phthalocyanine derivatives [132] 
VZV 
Viral envelope (prevention of viral adsorption 
and host penetration) 
Phthalocyanine derivatives [131] 
HIV Major capsid protein p24 Hypericin [111] 
HIV-1 
Loss of infectivity; loss of fusion function; 
membrane proteins cross-links 
Hypericin [30] 
Loss of infectivity; loss of fusion function; 
membrane proteins cross-links 
Rose bengal [30] 
p24 and gp120 proteins; protein cross-links MB [34] 
Inhibition of cell fusion activity of Env proteins 
Natural and sulfonated 
tetraarylporphyrins 
[36] 
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Table 4. Cont. 
Virus Type of damage PS Reference 
Enveloped-
mammalian viruses 
   
VSV 
Loss of infectivity; loss of fusion function; cross-
linking of G and M proteins 
Hypericin [30] 
Loss of infectivity; loss of fusion function; cross-
linking of G and M proteins 
Rose bengal [30] 
Inhibition of fusion of the envelope to Vero cells; 
G protein 
MB [81] 
Inhibition of fusion of the envelope to Vero cells; 
G protein 
Aluminum phthalocyanine 
tetrasulfonate 
[81] 
G and M proteins; protein cross-links Phthalocyanine derivatives [82] 
G, M, L and N proteins; protein cross-links Chlorophyll derivatives [77] 
Influenza virus 
Loss of infectivity; loss of fusion function; cross-
linking of G and M proteins 
Hypericin [30] 
Loss of infectivity; loss of fusion function; cross-
linking of G and M proteins 
Rose bengal [30] 
Loss of infectivity; HA fusion protein; protein 
cross-links 
Rose bengal [108] 
Sendai virus 
Loss of infectivity; loss of fusion function; cross-
linking of G and M proteins 
Hypericin [30] 
Loss of infectivity; loss of fusion function; cross-
linking of G and M proteins 
Rose bengal [30] 
Vaccinia virus Histidine residues in virus proteins Rose bengal [86] 
Human 
cytomegalovirus 
Viral envelope (reduced ability to adhere to and 
penetrate host cells) 
Merocyanine 540 [45] 
Sindbis virus 
Viral envelope (reduced ability to adhere to and 
penetrate host cells) 
Merocyanine 540 [47] 
Viral capsid protein Hypericin [133] 
Friend 
erythroleukemia virus 
Viral envelope (reduced ability to adhere to and 
penetrate host cells) 
Merocyanine 540 [134] 
Non-enveloped 
mammalian viruses 
   
Adenovirus Not damaged Phthalocyanine derivatives [131] 
Enterovirus 71 
Appearance/disappearance of protein bands; 
increase of the protein band intensity 
Methylene blue [85] 
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Table 4. Cont. 
Virus Type of damage PS Reference 
Non-enveloped 
bacteriophages 
   
T7 phage 
Protein capsid; loosening of the protein-DNA 
interaction 
Glycoconjugated meso-
tetraarylporphyrins 
[64] 
Capsid and core proteins; loosening of protein-
DNA interaction 
Glycoconjugated meso-
tetraarylporphyrins 
[87] 
Capsid proteins; protein cross-links 
meso-Tetrakis(1-
methylpyridinium-4-
yl)porphyrin 
[88] 
Capsid proteins; protein cross-links Polyhydroxylated fullerene [57] 
M13 phage Coat protein 
Methylene blue 
Aluminum phthalocyanine 
tetrasulfunate 
[81] 
PRD1 phage 
Capsid proteins; protein cross-links; 
phospholipids (less affected) 
Polyhydroxylated fullerene [57] 
Qβ phage 
Coat and maturation (A) proteins; formation of 
protein carbonyls;  
RNA-protein cross-links 
Methylene blue [89] 
RNA-protein cross-links 
Methylene blue 
 
[92] 
MS2 phage A protein Polyhydroxylated fullerene [57] 
4.2.1. Damage on Mammalian Viral Outer Structures 
It has been shown that enveloped viruses can be inactivated due to protein damage [30,82,83,131]. 
However, while the same treatment is reported to be ineffective against some non-enveloped viruses 
[83,131], the results from Wong et al. [85] showed that even a non-enveloped virus can be efficiently 
inactivated due to the damage induced by PDI to its viral proteins (Table 4). 
The proteins in the viral envelope of HSV-1 were considered to be major targets of merocyanine 
540 photosensitization [45]. Some phthalocyanine derivatives have been shown to induce cross-links 
in HSV protein that might be responsible for the observed loss of infectivity [132]. Protein analysis by 
SDS-PAGE, after treatment with phthalocyanine derivatives, revealed irreversible changes in the 
HSV-1 envelope proteins, which were reflected by the loss of many proteins, the appearance of 
cross-linked material on the top of the gel and by alterations in the molecular mass and molecular 
charge of the proteins. These alterations contribute, in all likelihood to HSV-1 inactivation [83].  
In VSV treated with 3.75–30 µL mL−1 of chlorophyll derivatives and light, the M protein band was 
not detected, which was accompanied by a decrease in the intensity of the G protein band [77]. Large 
complexes of proteins were also detected on the top of the gel, indicating that viral PDI cross-linked 
the proteins [77]. Using a fusion assay and protein analysis, it was shown that MB and AlPcS4 caused 
a decrease in the intensity of the G-protein (which is known to play a crucial role in binding VSV to 
the host cell) band and a slight decrease in the intensity of M protein (matrix protein) band and protein 
cross-links. However, the observed damage in viral proteins could not account for VSV PDI [82]. VSV 
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was inactivated by MB and phthalocyanine derivatives, which inhibited the fusion of the virus 
envelope to Vero cells. However, the degree of this inhibition was small compared to the extent of 
virus inactivation (43% inhibition vs. 4.7 log or 99.998% inactivation, for MB) [81]. Abe and 
Wagner [81] also found few changes in the relative abundance of VSV G protein after MB and AlPcS4 
phototreatment, and they also observed additional protein bands on SDS-PAGE analysis [81]. It was 
found, by Western blot analysis, that HIV-1 p24 and gp120 proteins were altered in size, possibly due 
to cross-linking, after MB phototreatment [34]. However, using the same PS, AlpcS4 and MB, no 
changes in protein patterns after SDS-PAGE of the viral proteins were observed, under conditions that 
caused complete VSV inactivation [135]. 
The results from Vzorov et al. [36] indicated that the porphyrins inhibited the cell fusion activity of 
HIV Env proteins (a biological function that is important for viral entry as well as induction of viral 
cytopathic effects) when expressed from recombinant vectors. These results showed that the viral Env 
protein is an important target of these compounds [36]. 
PDI of influenza virus by rose bengal altered the HA fusion protein and led to protein cross-links [108]. 
Photoinactivation of vaccinia virus with rose bengal significantly altered the concentration and 
oxidized histidine in vaccinia virus protein, suggesting that inactivation was attributed to alterations in 
viral proteins, as opposed to nucleic acids [86]. 
Treatment of of influenza and Sindbis viruses by hypericin [30], lead to an extensive cross-linking 
of the envelope proteins, which may have impaired the capacity of the viruses to adhere to and 
penetrate the host cells. 
The protein profile of the non-enveloped enterovirus 71 was considerably altered after a low dose 
PDI and a MB concentration ≥0.5 µM, as revealed by a smearing and the disappearance of several 
protein bands [85]. However, enterovirus 71 PDI was also due to damages in the viral genome [85].  
4.2.2. Damages on Bacteriophage Outer Structures 
In spite of the limited available data for enveloped bacteriophages, substantially higher 
photoinactivation rates compared with other non-enveloped phages were described [94]. The 
photoinactivation by merocyanine 540 of four bacteriophages, two non-enveloped phages without 
lipids (phi X174 and T7), a non-enveloped phage with lipids (PRD1), and an enveloped phage with an 
external lipoprotein envelope (phi 6) was studied by Lytle et al. [94]. The survival curves of the 
different viruses clearly demonstrated different levels of sensitivity to photoinactivation by this PS, 
with phi 6 being the most sensitive, followed by T7 (21-fold less sensitive). While both PRD1 and  
phi 6 have lipid components, only phi 6 was photoinactivated by the PS. Thus, the internal lipid 
components of PRD1 were not sufficient to allow photoinactivation by merocyanine 540. A higher 
inactivation rate with a fullerene derivative was also observed by Hotze et al. [57] for a phage without 
lipids (T7 phage) than for PRD1 phage. The dissimilarities in phage composition resulted from 
differential resistance to singlet oxygen by the outer structures, since PRD1 has a double capsid with 
an internal lipid membrane, whereas T7 has a single proteinaceous capsid lacking lipids, and both 
phages contain double stranded DNA with similar GC content (48% for T7 and 51% for PRD1) [57]. 
Phage proteins were significantly affected by photosensitization (30–92%) when compared to the 
relatively smaller effect on nucleic acids in both PRD1 and T7, and lipids in PRD1 phage (≤13%), as 
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assessed by FTIR spectra analysis [57]. The higher T7 phage inactivation is consistent with greater 
damage to its proteinaceous capsid. Besides this, SDS-PAGE analysis further evidenced that oxidative 
cross-linking of capsid proteins induced by exogenous singlet oxygen is the likely cause of phage 
inactivation [57]. The high propensity for MS2 phage inactivation by this PS (compared to PRD1 and 
T7 phages) possibly arises from damage to its A protein, which is necessary for infecting its host 
Escherichia coli since it contains highly reactive amino acids such as methionine, cysteine, histidine, 
and tyrosine and not to damages to the nucleic acid [57]. Glycosylated substituted porphyrins led to 
structural changes at the protein capsid and/or loosening of the protein-DNA interaction, which can be 
responsible for T7 phage inactivation [64]. Besides of the alteration of the DNA structure, the 
phototreatment pointed to significant alterations in the protein structure and/or in the DNA-protein 
interaction, which may be the cause of photodynamic inactivation [87,88]. The alterations in the DNA 
secondary structure might also be the result of photochemical damage in phage capsid proteins and 
consequent disruption of the phage particle. Photomodification of core proteins can also lead to phage 
inactivation, even if the primary structure of the DNA part is preserved, since these proteins play an 
important role in the early events of infection and DNA penetration [87]. The damage of T7 
nucleoprotein is a complex process and clearly both phage DNA and protein capsid are affected by 
photoreactions [88]. Irradiation of Qβ bacteriophage in the presence of increasing concentrations of 
MB resulted in exponentially increasing amounts of viral RNA-protein cross-linkage products, and this 
is probably the most important event in viral inactivation [92]. The RNA genome of Qβ bacteriophage 
contained sufficiently lethal lesions following MB plus light exposure to account for the resulting 
phage inactivation. Nevertheless, the data also indicate that the protein component of the phage 
somehow contributes to the inactivation of the phage [122]. The protein component of Qβ phage is 
involved in the process of photoinactivation because the formation of protein carbonyls and  
RNA-protein cross-links were efficiently formed by MB plus light exposure [89]. The close correlation 
of cross-link formation with phage inactivation and the expectation that even one such cross-link in a 
phage genome would be lethal makes the RNA-protein cross-link lesion a strong candidate for the 
primary inactivating lesion of Qβ phage exposed to MB and light [122].  
Little alteration of M13 phage proteins on SDS-PAGE after MB and AlPcS4 photoinactivation was 
observed by Abe and Wagner [81]. The results of Zupán et al. [136], suggested that the tetracationic 
porphyrin meso-tetrakis(1-methylpyridinium-4-yl)porphyrin did not interact with capsid proteins 
and did not disturb protein-DNA interaction, even if it has a strong stabilization effect on the 
intraphage DNA. 
5. Resistance to PDI and Recovery of Viability 
The development of increasing numbers of antiviral agents over the past decades, in the same way 
as with antibiotics, has provided the clinician with therapeutic options previously unavailable. With the 
increasing utilization of antiviral drugs, however, has come an enhanced appreciation of the 
development of antiviral resistance [1,7,137,138,139,140]. Drug resistance is costly to the health 
service, to the patient who fails to gain maximum therapeutic benefit, and for the community in which 
resistant viruses may be spread [9].  
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There is now an urgent need for the development of novel, convenient and inexpensive measures 
for combating antimicrobial-untreatable infections and limiting the development of additional 
antimicrobial resistant microorganisms. Photodynamic technology may provide one approach to meet 
this need, both in terms of therapy and in terms of sterilization, by a mechanism that is markedly 
different from that typical of most antimicrobials [1,141,142]. 
As mentioned before, photosensitization involves the generation of singlet oxygen and free radical 
species, which cause molecular damage. Whether microorganisms could develop resistance to these 
active oxygen species is still questionable [143] and, consequently, the development of microbial 
resistance to photosensitization is still under debate. Until now, the development of microbial 
resistance to PDI is not known and is thought very improbable to be developed. In general, the 
development of resistance to PDI by microbial strains should be considered as an unlikely event since 
this process is typically multi-target, with ROS causing damage to many microbial components, which 
is at a variance with the mechanism of action of most antimicrobial drugs [139,144,145]. In contrast to 
most common antimicrobials, the number of molecular alterations required to ensure survival would be 
too great and the microorganism would require multi-site mutations to become highly resistant, an 
event with significantly lower probability than single-site mutations, which is often sufficient for 
conferring resistance to small-molecule inhibitors [42,146]. This particular property of antimicrobial 
PDI is important regarding the repeated treatment of chronic and/or recurrent infections [139]. 
Antimicrobial PDI, when compared to standard treatments which may require application for several 
weeks to achieve an effective killing of the microorganism, shortly after initiation of light exposure, 
exhibits serious and irreversible damage of microorganisms [66,68]. This damage does not allow the 
creation or operation of any kind of anti-drug or mutagenic mechanism. Antimicrobial PDI is therefore 
very effective and, up until now, no photosensitization-resistant mutants have been found [68]. 
5.1. Resistance of Mammalian Viruses and Recovery of Viability after Photosensitization 
Data from North et al. [33] show that HIV azidothymidine (AZT)-resistant strains were as 
susceptible as the AZT-sensitive ones to photosensitization with a benzoporphyrin derivative. This 
finding comes as no surprise since the mechanisms of action of AZT (inhibition of reverse 
transcription) and light-activated benzoporphyrin derivative are different. Thus, mutations in the virus 
that occur at the reverse transcriptase level will not affect photodynamic destruction [33]. 
Studies focusing on the possible development of viral resistance are extremely scarce and little is 
known about the recovery of viral viability after consecutive photodynamic treatments. 
5.2. Bacteriophage Resistance and Viability Recovery after Photosensitization 
Concerning bacteriophages, there is only one study focusing on the possible development of viral 
resistance after photosensitization [68]. After 10 consecutive cycles of photodynamic treatment, a  
T4-like phage, in the presence of the tricationic porphyrin 5-(pentafluorophenyl)-10,15,20-tris(1-
methylpyridinium-4-yl)porphyrin (Tri-Py+-Me-PF) at 5.0 µM under white light irradiation, exhibited 
no changes in the rate of photoinactivation during the course of the experiments, meaning that no 
resistance was observed. If phage resistance would occur, important reductions on phage 
photoinactivation efficiency would be detected between experiments. Besides that, T4-like phage did 
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not recover its viability after exposure to Tri-Py+-Me-PF during 120 min of irradiation [68]. In a 
preliminary study by Perdrau and Todd [12], all attempts at reactivating the inactivated Staphylococcus 
phage by MB were unsuccessful.  
6. Factors Affecting Viral PDI 
6.1. Effect of the Number of Charges, Symmetry, Size of Meso Substituent Groups and Photosensitizer 
Concentration 
It has been shown that the location and binding site of the PS, which is highly dependent on the 
structure and intramolecular charge distribution, is an important factor in microbial PDI [143,147]. 
In terms of molecular structure, molecular charge is important in determining antimicrobial activity. 
Positively charged PS are generally more efficient and can act at lower concentrations than neutral and 
anionic PS molecules [144]. The positive charges on the PS molecule appear to promote a tight 
electrostatic interaction between the positively charged PS and the negatively charged sites at the viral 
capsids and envelopes, orientating the PS toward sites which are critical for the stability and 
metabolism of a particular microorganism [44,147,148]. This kind of association increases the 
efficiency of the photoinactivation process. 
Cationic PS photodamage can be induced in nucleic acid or viral outer structures by PS binding or 
by PS localized in its vicinity [136]. For instance, it is more likely that positively charged PS will be 
effective in causing nucleic acid damage than will neutral or anionic congeners, which mainly act 
against the outer side of the microorganism [149]. 
The symmetry and the size of the chain of meso substituent groups also affect the photodynamic 
effect. PS with opposite charged groups are more symmetrical than PS with adjacent charged groups. 
The adjacent positive charges in the PS macrocycle should result in a molecular distortion due to 
electrostatic repulsion [150]. The toxicity of a PS can be modulated by the introduction of selected 
substituents on the macrocycle periphery. In this way, the physicochemical properties of a synthetic PS 
can be manipulated in order to enhance its interactions with the structural features of the viruses, such 
as viral capsids, and to minimize the interactions with plasma membranes or mammalian cell 
membranes [44].  
The amphiphilic nature of a PS is another important feature affecting PDI efficiency and can be 
modulated by the introduction of adequate functionalities in the macrocycle periphery, such as 
different numbers of positive charges, an asymmetrical charge distribution, or introduction of aromatic 
hydrocarbon side chains [16,151].  
PS concentration is also an important parameter that must be taken into account since viral PDI was 
shown to be strongly influenced by PS concentration. Increasing the PS concentration reduces the time 
needed to achieve complete viral inactivation, thus increasing the efficiency of a particular PDI 
protocol [66]. 
6.1.1. Mammalian Viruses PDI 
Complete inactivation of VSV (4.2 log) can be obtained by treating it with 1.0 µM of the anionic 
phthalocyanine derivative AlPcS4 and 5 min illumination with red light. For the neutral phthalocyanine 
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derivative (Pc4), complete inactivation (4 log) was achieved using a much lower amount of PS (4.5 nM) 
in combination with 10 min illumination [82]. The inactivation of VSV in PBS showed a linear 
relationship with illumination time [82]. Inactivation of the fusion activity of VSV, influenza and 
Sendai viruses was reached with nanomolar concentrations of hypericin and rose bengal and was 
absolutely dependent upon light and increased with increasing time of illumination [30]. HAV in PBS 
or plasma was completely inactivated within 10 min (>3.7 log) by the cationic symmetric porphyrin 
meso-tetrakis(1-methylpyridinium-4-yl)porphyrin. In contrast, inactivation of HAV to 3.6 log with the 
anionic symmetric porphyrin meso-tetrakis(4-sulfonatephenyl)porphyrin required 90 min [44]. The 
rate and extent of inactivation appeared to vary with the nature of the meso substituent groups [44]. 
HIV and VSV lost infectivity upon illumination with hypericin and rose bengal in a concentration-
dependent manner [30]. 
6.1.2. Bacteriophage PDI 
MS2 phage inactivation has been observed with neutral porphyrin derivatives. However, this 
required higher irradiation periods (30 min) than for the cationic ones (1 min) [44]. Neutral 
glycosylated substituted porphyrins can also significantly photoinactivate the T7 phage [64,87]. The 
T4-like phage PDI was achieved by exposing the phage in the presence of six cationic porphyrins at 
different concentrations (0.5, 1.0 and 5.0 µM) to white light for 270 min. The results showed that 
phage photoinactivation varied according with the PS concentration, with higher concentrations being 
the most efficient ones [66]. The T4-like phage PDI also varied with the number of porphyrin charges, 
with tri- and tetracationic porphyrin derivatives being more effective in viral inactivation that the 
dicationic ones, which inactivated the phage below the limit of detection. Tetra- and tricationic 
porphyrin derivatives (meso-tetrakis(1-methylpyridinium-4-yl)porphyrin and 5-(pentafluorophenyl)-
10,15,20-tris(1-methylpyridinium-4-yl)porphyrin, respectively) lead to complete T4-like phage 
inactivation (∼7 log) after 270 min of irradiation with 40 W m−2 [66]. This tetracationic porphyrin 
showed similar results in another study (7 log of reduction) for lambda phage inactivation, when 
irradiated with light of 658 nm [58]. Increasing porphyrin concentration at a fixed light dose leads to 
increased viral inactivation [58]. A concentration-dependent effect was also detected with a porphyrin 
derivative [87], but over 2.0 µM of PS the process was saturated. A further increase in porphyrin 
concentration did not lead to a higher inactivation rate of T7 phage. Aggregation and/or 
photobleaching of PS are likely explanations [87]. Cationic meso-tetrakis(1-alkylpyridinium-4-
yl)porphyrin derivatives with different alkyl substituent groups were tested for MS2 phage inactivation 
but, with the exception of 5,10,15,20-tetrakis(4-sulfonatophenyl)porphyrin, showed toxicity even in 
the absence of light [44].  
In a study conducted by Gábor et al. [64], the porphyrin derivative with symmetrical glycosylated 
groups was found to be twice as effective as the asymmetrical one on the inactivation process of T7 
phage. According to Costa and colleagues [66], the rate of T4-like phage inactivation was also 
dependent on the lipophilic character of the meso-substituent groups. The presence of a lipophilic aryl 
group in one of the meso positions of the porphyrin core appears to have an important role in phage 
inactivation, affecting the rate and efficiency of T4-like phage [66]. Casteel et al. [44] have also 
observed differences in the photoinactivation rate of MS2 phage when they used PS with different 
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alkyl substituent groups and concluded that the rate and extent of inactivation appeared to vary with 
the nature of the meso substituent groups. 
6.2. Effect of Different Light Sources and Fluence Rate on Antimicrobial PDT  
PDT requires a source of light to activate the PS by exposing it to visible or near-visible light at a 
specific wavelength [152]. The light source for PDT must also exhibit suitable spectral characteristics 
coinciding preferentially with the maximum absorption wavelength range of the PS, applied in order to 
generate enough ROS to produce an efficient toxic effect [153]. 
In parallel with the advances in chemistry (related with the discovery and synthesis of new and 
more efficient PS) there has also been much activity in developing new light sources, better suited 
for the photosensitization process. Briefly, these include user-friendly lasers frequently based on solid 
state laser diodes, as well as inexpensive light emitting diodes (LED) and filtered broad-band 
lamps [154].  
PS activation has been achieved via a variety of light sources, such as arc plasma discharge lamps, 
metal halogen lamps, slide projector illumination assemblies, and a variety of lasers. For treatment of 
larger areas, non-coherent light sources, such as tungsten filament, quartz halogen, xenon arc, metal 
halide, and phosphor-coated sodium lamps, are in use. Recently, non-laser light sources, such as LED, 
have also been applied in PDT. These light sources are much less expensive and small, lightweight and 
highly flexible, its lifetime can reach up to one hundred thousands hours, and can be manufactured to 
wavelengths that activate commercially available PS [152,155–159]. 
At first glance, the available literature on fluence rate effects for PDT seems contradictory. Some 
studies indicate less damage at low fluence rate, others indicate more killing at lower, compared to 
higher, fluence rates for the same total fluence and some indicate no influence of fluence rate at all 
[152,157,158]. A reduction in the fluence rate lowers the rate of oxygen consumption, thereby 
extending the radius over which singlet oxygen may be formed and consequently increasing the 
phototoxic effect [159]. Qin et al. [160] showed that an increase in the fluence rate increases microbial 
damage, although, it seems to have an upper limit of photons to observe this effect. Since each PS 
molecule can only absorb one photon at a time, when the number of light photons bypasses the number 
of PS molecules, the PS will no longer be able to absorb the photons “in excess” and the rate of PDI 
will not increase. In fact, if the number of photons is higher than this limit, the antimicrobial effect will 
decrease because the dye in suspension will not absorb all the excess light [160]. Schindl et al. [161] 
referred that the biological effect of light depends on the fluence, irrespective of the time over which 
this dose is delivered. Maclean et al. [162] also indicate that the inactivating light may be applied at 
high irradiance over a short time or at lower irradiance over a longer time. A numerical model, 
assuming that the rate of photodynamic damage occurring at time t is proportional to the fluence rate at 
that time and the local concentrations of PS and oxygen can be established. However, according to this 
model, relatively low fluence rates can be nearly as effective as high fluence rate sources if applied 
over the same period of time [163]. 
There is also a direct correlation between the phototoxic effect and the PS concentration and light 
fluence. With a lowering of the PS concentration, more light has to be applied to achieve identical 
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effects, and vice versa. Lower doses of PS require higher activating light fluences, and higher fluence 
requires a longer duration of light application [96].  
6.2.1. Effect of Light on Mammalian Viruses PDI 
The effects of dengue virus inactivation were increased with the increase of MB concentration, the 
enhancement of power density of the light source and the extension of illumination time, as well as the 
decrease of illumination distance. This enabled the narrow bandwidth light system to kill or inactivate 
the enveloped virus at much greater distance in much shorter time [74]. VSV in the presence of MB 
was rapidly inactivated by red (provided by LED incident light at 272 W cm−2) or green-yellow light 
(provided by low-pressure sodium lamps at a fluence rate of 165 W cm−2) but slower by white light 
(provided by a bank of fluorescent tubes at a fluence rate of 42 W cm−2) [46], showing that higher 
power densities produce a high rate of viral inactivation than low fluence rates. Wagner et al. [164] 
also showed that red light of 9 W m−2, given at a total dose of 1.8 × 104 and 3.2 × 104 J m-2, inactivated 
MB-treated VSV by 6 and ≥7 log, respectively. VSV inactivation was linearly dependent on the 
fluence rate of red light illumination [165].  
6.2.2. Effect of Light on Bacteriophage PDI 
In terms of what is known about phage PDI, only one study focusing on the effect of different light 
sources and power densities [67] exists. In this study, cationic porphyrin derivatives (meso-tetrakis(1-
methylpyridinium-4-yl)porphyrin and 5-(pentafluorophenyl)-10,15,20-tris(1-methylpyridinium-4-
yl)porphyrin), when irradiated with different sources of light (fluorescent PAR lamps, sun light and 
halogen lamp) with fluence rates ranging from 40 W m−2 to 1690 W m−2, efficiently photoinactivated 
non-enveloped phages. All light sources tested lead to reductions of about 7 log for the somatic T4-like 
phage. However, the rate and the extent of inactivation were dependent on the light source, namely 
when low fluence rates were used (40 W m−2) and on the energy dose, being considerably more 
effective when light was delivered at a lower fluence rate. However, depending on the light source 
used, different irradiation periods were required to inactivate T4-like phage to the limits of detection. 
The results also showed that the efficacy of T4-like phage inactivation, using the same fluence rate, 
was dependent on the light source used, in particular when the light is delivered at a low fluence rate. 
M13 phage was phototreated with 5.0 µM MB and was inactivated in an irradiation dose-dependent 
manner [52]. Kastury and Platz [58] showed that increasing the concentration of a PS at a fixed light 
dose leads to increased viral inactivation as does an increase in the total light exposure at a fixed PS 
concentration. The inactivation rate of T1 bacteriophage increased with increasing fluence rate, 
indicating that the distance of the sample from the light source is a variable which must be 
controlled [73]. At higher PS concentrations, the inactivation rate reaches a maximum and then 
decreases, because the filtering effect of the dye decreases the effective fluence rate [73]. In a simple 
model purposed by Lee et al. [56], the phage survival ratio can also be considered as a decreasing 
exponential fraction of the light fluence (assuming that the fluence is uniform throughout the system). 
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7. Conclusion 
The efficiency of different types of PS in viral PDI has been proved for different types of 
mammalian viruses and bacteriophages, whether they are enveloped or non-enveloped, for either DNA 
or RNA viruses. Even though enveloped viruses are more easily inactivated than non-enveloped ones, 
several studies confirm that non-enveloped mammalian viruses and phages can be efficiently 
inactivated by PDI. The type of viral nucleic acid has not been described as an important factor 
affecting viral photoinactivation but, as far as it is known, no studies specifically focus on the 
photoinactivation behaviour of DNA and RNA viruses. However, RNA phage MS2 was highly 
susceptible to photoinactivation when compared with DNA phages under the same conditions of 
photosensitization. 
The type of mechanisms involved in the process of viral photosensitization was already elucidated 
and singlet oxygen and free radical species were identified as important contributors for an effective 
viral PDI. However, the contribution of singlet oxygen seems to be more pronounced in mammalian 
viruses and bacteriophage PDI. There are, however, few studies simultaneously comparing the 
contribution of both types of mechanisms (type I and type II) involved in viral PDI. The primary 
targets for the photoinactivation of viruses, whether treating mammalian viruses or phages, are the 
outer structures. Although there are several studies about the specific effects of PDI on viral proteins, 
for different types of mammalian viruses and phages, there are no studies concerning the specific 
effects of PDI on viral lipids. However, it has been clearly shown that enveloped viruses are more 
easily inactivated than their non-enveloped counterparts, which imply that the lipids present on viral 
envelopes are important targets of viral PDI. 
PS are effective in inactivating the phages to the limits of detection in a way that they do not 
recover viability, avoiding the development of viral resistance. Nothing is known yet for the particular 
case of mammalian viruses but, as the viral targets are the same for mammalian viruses and phages, it 
is also expected that no resistance will be developed in the case of mammalian viruses. Besides that, 
antiviral PDI is equally effective whether the mammalian virus is sensitive or resistant to conventional 
antiviral agents. Taking into account all these advantages, PDI for viral inactivation can be regarded as 
a promising alternative therapy to conventional antiviral treatments, namely for the disinfection of 
blood and blood products, preventing viral contamination and for the treatment of wound and burn 
infections. Viral PDI has a fast mode of action and has also the additional benefits of being more 
economical and an environmental friendly technology, which might be successfully used also in the 
environmental field for wastewater, drinking water and fish-farming water disinfection. 
Different PS concentrations and different light sources and fluence rates were tested, showing that 
they are important PDI parameters that must inevitably be taken into account when a viral 
photosensitization protocol has to be elaborated. The inactivation of mammalian viruses and phages 
can be attained at micromolar-level PS concentrations and different light sources are equally effective, 
depending on the final dose at which the viruses are exposed to. Besides that, PS can also be 
modulated by the addition of different meso substituent groups and positive charges in order to 
facilitate their interactions with the viruses, making them more efficient for mammalian viruses and 
phage PDI. 
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The similarity of the results obtained for mammalian viruses and bacteriophages show that they 
exhibit a similar behaviour when submitted to viral photoinactivation techniques: (i) the PS used for 
viral PDI were equally effective in the photoinactivation of mammalian viruses and bacteriophages; 
(ii) the mechanism of mammalian viruses and bacteriophage photosensitization involves the 
production of singlet oxygen (type II mechanism) with a slight contribution of free radical species 
(type I mechanism); (iii) singlet oxygen and free radicals were shown to affect viral nucleic acids and 
also the proteins and lipids present in the mammalian viruses and bacteriophage outer surfaces, with 
the latter being considerably more affected by PDI; and (iv) the rate and extent of mammalian viruses 
and phage PDI is also affected by the same factors, like the PS concentration and number of positive 
charges, the nature and position of meso substituent groups, the fluence rate and energy dose. 
Consequently, it is important to persist in the development of more PDI phage studies to clarify some 
aspects of viral PDI, such as influence of viral nucleic acid type (DNA or RNA) in the 
photoinactivation efficiency and the possibility of viral resistance development and viability recovery 
after photosensitization. It will also be important to study the synergistic effect between viral PDI and 
antiviral classical methodologies using bacteriophages as models of mammalian virus’ photoinactivation. 
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